BioNTech

BioNTech’s Spinoff Deadline Nears as ASCO Data Bolster Oncology Pipeline

ASCO双刀出鞘：BioNTech肺癌双抗控制率100%，HER2 ADC冲刺审批

双拳出击：BioNTech在ASCO亮出肿瘤赛道底牌

Brett Shapiro -

BioNTech Banks on Broad Cancer Pipeline and Cost Discipline as ASCO Data Rolls In

angelina -

BioNTech’s ASCO Week: A $622 Million Loss and a Shot at a First U.S. Cancer Approval

BioNTech’s Oncology Pipeline Flexes Its Muscle: BNT323 Data Impress as Pumitamig Waits in the Wings

kashif hafeez -

BioNTech’s €532 Million Loss Accelerates Restructuring and a New Executive Compensation Playbook

kashif hafeez -

BioNTech’s High-Stakes Pivot: Cancer Data, Factory Shutdowns, and a Founder Exodus

angelina -

BioNTech’s May Marathon: Earnings, a Shareholder Vote, and a Rival’s Data Test the Oncology Pivot

Brett Shapiro -

BioNTech’s Double Play: Cancer Vaccine Milestone and a New Legal Front Against Moderna

angelina -

BioNTech’s Defining Fortnight: Insider Sales, Founder Exodus, and a Pipeline Under the Microscope

angelina -

BioNTech’s €17 Billion War Chest Faces a Defining May as Insider Sale Precedes Earnings

Brett Shapiro -

BioNTech’s Cancer Bet Gathers Pace as Pipeline Data and Leadership Shifts Loom

Brett Shapiro -

BioNTech’s Shareholder Vote to Cement Strategic Overhaul

kashif hafeez -

BioNTech’s Cash Cushion Fuels High-Stakes Oncology Race

angelina -
123...9Page 2 of 9